Fractures, Bone
Breaks in bones.
Subtype terms (28)
More specific conditions that are subtypes of Fractures, Bone in the MeSH hierarchy.
- Ankle Fractures
20 drugs (15 approved, 5 experimental)
- Elbow Fractures
- Femoral Fractures
12 drugs (11 approved, 1 experimental)
- Fibula Fractures
- Fracture Dislocation
4 drugs approved
- Fractures, Avulsion
- Fractures, Closed
11 drugs approved
- Fractures, Comminuted
1 drug approved
- Fractures, Compression
6 drugs approved
- Fractures, Malunited
- Fractures, Multiple
- Fractures, Open
12 drugs (11 approved, 1 experimental)
- Fractures, Spontaneous
2 drugs approved
- Fractures, Stress
11 drugs (7 approved, 4 experimental)
- Fractures, Ununited
1 drug experimental
- Humeral Fractures
4 drugs approved
- Intra-Articular Fractures
1 drug approved
- Knee Fractures
- Osteoporotic Fractures
10 drugs (8 approved, 2 experimental)
- Periprosthetic Fractures
- Radius Fractures
10 drugs (7 approved, 3 experimental)
- Rib Fractures
21 drugs (19 approved, 2 experimental)
- Shoulder Fractures
7 drugs (6 approved, 1 experimental)
- Skull Fractures
- Spinal Fractures
5 drugs (4 approved, 1 experimental)
- Tibial Fractures
15 drugs (8 approved, 7 experimental)
- Ulna Fractures
2 drugs approved
- Wrist Fractures
Drugs by status
Phase 4 trials (60)
Phase 3 trials (20)
- simvastatin
- talc
- bone morphogenetic protein-2
- atenolol
- ketotifen
- bone marrow derived mesenchymal stem cells
- potassium
- magnesium oxide
- acetylsalicylic acid
- toremifene
- traumeel
- ramipril
- allogeneic adipose derived mesenchymal stem cell
- umbilical cord mesenchymal stem cells
- phosphorus
- isopropyl alcohol
- iodine povacrylex
- hydrochlorothiazide
- trebananib
- olive
Phase 2 trials (22)
- calcium carbonate
- abaloparatide
- palmitoylethanolamide
- parathyroid hormone
- somatropin
- lornoxicam
- lithium
- enoxaparin
- calcitriol
- allogeneic osteoblastic cells
- amniotic epithelial cells
- autologous iliac crest
- autologous bone marrow derived mesenchymal cells
- mesenchymal stem cells with bmp2
- autologous mesenchymal stem cells
- wharton's jelly mesenchymal stem cells
- medium chain triglyceride
- sodium bicarbonate
- cephalexin
- autologous adipose-derived mesenchymal stem cells
- allogeneic mesenchymal stem cells
- ARANEUS
Phase 1 trials (7)
Other trials (26)
- bifidobacterium animalis
- prednisone
- eldecalcitol
- vitis vinifera
- icosapent ethyl
- platelet-rich plasma
- nalbuphine
- pamidronate
- alendronic acid
- remimazolam
- sitagliptin
- celecoxib
- troglitazone
- spironolactone
- yunnan baiyao
- polymethylmetacrylate
- pioglitazone
- multivitamins
- naringen
- amiloride
- codeine
- dalteparin
- ergocalciferol
- omega-3 fatty acids
- fish oil
- cocoa extract
Organizations
Organization Involved with Phase 4 Indications (105)
- Abbott
- Radius Health
- Takeda
- Forest Laboratories
- Merck
- Eli Lilly
- Pfizer
- Sanofi
- Wyeth
- Novartis
- GlaxoSmithKline
- Hamilton Health Sciences Corporation
- Mepha Ltd.
- Nycomed
- Fundacio Salut i Envelliment UAB
- National Institutes of Health (NIH)
- National Institute on Aging (NIA)
- United States Army
- Landstinget i Värmland
- Aarhus University
- Rockefeller University
- University of Pittsburgh
- Alameda Health System
- Baylor University
- Betanien Hospital
- Consorci Sanitari de Terrassa
- Cukurova University
- Damanhour University
- Geisinger Clinic
- University of Washington
- +75 more
Organization Involved with Phase 3 Indications (55)
- Amgen
- Fresenius
- Ipsen
- Eurofarma Laboratorios S.A.
- GTx
- Pluristem Ltd.
- Gamida Cell
- Fundación Pública Andaluza
- Swiss National Science Foundation
- University of Pennsylvania
- Baskent University
- Chang Gung University
- Chulalongkorn University
- Gerencia de Atención Primaria, Albacete
- Hormozgan University of Medical Sciences
- Instituto Mexicano del Seguro Social
- Jamaica Hospital Medical Center
- Johns Hopkins University
- Lancaster General Hospital
- Major Extremity Trauma Research Consortium
- Queen's University, Belfast
- Royan Institute
- Triemli Hospital
- University of East Anglia
- University of Maryland
- University of Seville
- University of Tehran
- University of Toronto
- University of Virginia
- University of Zurich
- +25 more
Organization Involved with Phase 2 Indications (41)
- Novo Nordisk
- Amorphical Ltd.
- Azelon Pharmaceuticals
- Trevena Inc.
- Vericel Corporation
- Viking Therapeutics, Inc.
- vTv Therapeutics
- Bone Therapeutics S.A
- United States Air Force
- Huazhong University of Science and Technology
- Banc de Sang i Teixits
- Barzilai Medical Center
- Broward Health
- Changhua Christian Hospital
- Cornell University
- Emdadi Kamyab Hospital
- Helen Hayes Hospital
- Hoosier Cancer Research Network
- Indiana University
- Lenox Hill Hospital
- Mansoura University
- Ohio State University
- University of Michigan
- University of Adelaide
- University of Athens
- South China Research Center for Stem Cell and Regenerative Medicine
- University of Cincinnati
- Lutheran Medical Center
- Hospital ASEPEYO Sant Cugat
- National Taiwan University
- +11 more
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (52)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- University of Manitoba
- Centro Hospitalar do Porto
- Changi General Hospital
- Harvard University
- HealthPartners Institute
- Hospital del Trabajador de Santiago
- Keele University
- Kuala Lumpur General Hospital
- KAT General Hospital
- KK Women's and Children's Hospital
- Lithuanian University of Health Sciences
- Lund University
- Medical University of Bialystok
- National University of Malaysia
- New York University
- NHS Lothian
- Oakland University
- Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust
- Universidad Autonoma de Nuevo Leon
- Thomas Jefferson University
- University of Rochester
- University of Rostock
- University of Thessaly
- VieCuri Medical Centre
- University of Alberta
- Zagazig University
- B.P. Koirala Institute of Health Sciences
- Bogomolets National Medical University
- Creighton University
- +22 more